Table 2.
Characteristics of enrolled studies to meta-analysis.
| First Author, Month/year | Country | Patients (n) | Female/Male | Age >18 median | Type of Cancer | COVID-19 Vaccine (2 doses) | Median Follow up after second dose | |
|---|---|---|---|---|---|---|---|---|
| 1 | Mahil et al., Oct 2021 (11) | Italy | 88 | 23/65 | 68 (61.5-73) | Solid tumor | BNT162b2 | 21 days |
| 2 | Ollila et al., Nov 2021 (12) | Island | 160 | 74/86 | 72 (65–79) | Hematologic | BNT162b2 & mRNA-1273 | N/M |
| Johnson & Johnson | ||||||||
| 3 | Roeker et al., May 2021 (13) | USA | 44 | 21/23 | 71 (37-89) | Hematologic | BNT162b2 & mRNA-1273 | 21 days |
| 4 | Shah et al., Nov 2021 (14) | NA | 89 | 51/38 | NA | Hematologic | BTN162b26 & mRNA-1273 | 14 days |
| 5 | Cavanna et al., Sep 2021 (15) | Italy | 257 | 144/113 | 65 (57–72) | Solid tumor | BNT162b2 & mRNA-1273 | 28 days |
| 6 | Monin et al., Aug 2021 (16) | UK | 24 | NA | 73 (64.5-79.5) | Solid & Hematologic tumors | BNT162b2 | 12 weeks |
| 7 | Shmueli et al., Sep 2021 (17) | Israel | 129 | 67/62 | 62 (32-84) | Solid tumor | BNT162b2 | N/M |
| 8 | Gounant et al., Nov 2021 (18) | French | 325 | 181/125 | 67 (27-92) | Solid tumor | BNT162b2 | 2-9 weeks |
| 9 | Perry et al., Aug 2021 (19) | Israel | 149 | 61/88 | 64 (1) | Hematologic | BNT162b2 | 14-21 days |
| 10 | Herishanu et al., Jun 2021 (20) | Israel | 167 | 55/112 | 71 (1) | Hematologic | BNT162b2 | 15 days |
| 11 | Massarweh et al., May 2021 (21) | Israel | 102 | 44/58 | 66 (64-80) | Solid tumor | BNT162b2 | 3- 54 days |
| 12 | Pimpinelli et al., May 2021 (22) | Italy | 92 | 43/49 | NA | Hematologic | BNT162b2 | N/M |
| 13 | Van Oekelen et al., Aug 2021 (25) | USA | 260 | 135/185 | 68 (1) | Hematologic | BNT162b2 | N/M |
| 14 | Karacin et al., Aug 2021 (24) | Turkey | 47 | 18/29 | 73 (64–80) | Solid tumor | inactivated vaccine | 4 weeks |
| 15 | Ariamanesh et al., Oct 2021 (7) | Iran | 364 | 217/147 | 54 (18–85) | Solid tumor | BBIBP-CorV | N/M |
| 16 | Addeo et al., August 2021 (25) | US/Europe | 131 | 59/72 | 63 (55–69) | Solid & Hematologic tumors | BNT162b2&mRNA-1273 | N/M |
| 17 | Pimpinelli, et al. July 2021 (26) | Italy | 42 | NA | NA | Hematologic | BNT162b2 | N/M |
| 18 | Oosting et al., Dec 2021 (27) | Netherlands | 503 | 260/243 | NA | Solid tumor | mRNA-1273 | N/M |
| 19 | Webber et al., Dec 2021 (28) | Italy | 291 | 173/118 | 68.2 (60–75) | Solid tumor | BNT162b2 | 21 days |
| 20 | Barrière et al., April 2021 (29) | France | 42 | NA | NA | Solid tumor | BNT162b2 | N/M |
| 21 | Astha Thakkar, Aug 2021 (30) | USA | 200 | 116/84 | 67 (27–90) | Solid & Hematologic tumors | BNT162b2&mRNA-1273 | 30 days |
| AD26.COV2. S | ||||||||
| 22 | A. Grinshpun, Sep 2021 (31) | Israel | 172 | NA | 62 (23–91) | Solid tumor | BNT162b2 | 77 days |
| 23 | Tal Goshen-Lago, July 2021 (32) | Israel | 232 | 100/132 | NA | Solid & Hematologic tumors | BNT162b2 | 14 days |
| 24 | Ithai Waldhorn, Oct 2021 (33) | USA | 154 | 70/884 | 67 (32–87) | Solid tumor | BNT162b2 | N/M |
| 25 | Mounzer Agha, Jan 2021 (34) | France | 67 | 32/35 | 65 (57–72) | Hematologic | BNT162b2 & mRNA-1273 | 23 days |
| 26 | Gabriel Revon-Riviere, June 2021 (35) | Israel | 13 | 11/2 | NA | Solid tumor | BNT162b2 | N/M |
| 27 | Florent Malard, Aug 2021 (36) | French | 195 | 117/78 | 69 (21.5-91.7) | Hematologic | BNT162b2 | 14 days |
| 28 | Ron Ram, June 2021 (37) | Israel | 80 | 36/44 | 65 (23–83) | Hematologic | BNT162b2 | N/M |
N/M, Not mentioned; NA, Not available.